CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Paracetamol and Caffeine +1 moredrug
Likely dose
Paracetamol and Caffeine 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01466348
NCT01466348Phase 4Completed
CompareCT.gov

Effects of a Common Cold Treatment on Cognitive Function

GlaxoSmithKline·interventional·Posted Nov 7, 2011·Updated Nov 25, 2013

In Brief

A Phase 4 clinical trial evaluating Paracetamol and Caffeine and Paracetamol for Common Cold. Completed, enrolled 72 participants across 1 site.

Detailed Summary

A reduction in alertness and lower levels of performance are commonly associated with the common cold. Paracetamol has been shown to be more effective than placebo in treating symptoms associated with upper respiratory tract infection; caffeine has been shown to increase levels of alertness and improve performance of people suffering from colds. This study will investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering from the common cold, when taking a novel paracetamol and caffeine combination verses paracetamol alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2011
Enrollment StartFeb 1, 2011
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.7 years ago

Interventions

Paracetamol and Caffeinedrug

Paracetamol 1000 mg and caffeine 130 mg

Paracetamoldrug

Paracetamol 1000 mg